Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls
Open Access
- 1 March 2012
- journal article
- case report
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 171 (4), 631-639
- https://doi.org/10.1007/s00431-012-1703-y
Abstract
Mucopolysaccharidosis II (MPS II), or Hunter syndrome, is an X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase. Affected patients suffer progressive damage to multiple organ systems and early mortality. Two thirds of patients also manifest cognitive impairment and developmental delays. MPS II can be extremely difficult to diagnose before irreversible organ and tissue damage has occurred because of an insidious onset and the overlap in signs and symptoms with common childhood complaints. This is particularly true of patients without cognitive impairment (attenuated phenotype). Although not curative, early treatment with enzyme replacement therapy before irreversible organ damage has occurred may result in the greatest clinical benefit. Here, the signs, symptoms, and surgical history that should trigger suspicion of MPS II are described, and the diagnostic process is reviewed with a focus on practical considerations and the avoidance of common diagnostic pitfalls. Once a diagnosis is made, multidisciplinary management with an extended team of pediatric specialists is essential and should involve the pediatrician or family practice physician as facilitator and medical home for the patient and family. Conclusion: Because routine newborn screening is not yet available for MPS II, the involvement and awareness of pediatricians, family practice physicians, and pediatric specialists is critical for early identification, diagnosis, and referral in order to help optimize patient outcomes.Keywords
This publication has 47 references indexed in Scilit:
- Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseOrphanet Journal of Rare Diseases, 2011
- Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type IIJournal of Inherited Metabolic Disease, 2010
- Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome SurveyOrthopedic Reviews, 2010
- Expression of the disease on female carriers of X-linked lysosomal disorders: a brief reviewOrphanet Journal of Rare Diseases, 2010
- Mucopolysaccharidosis VIOrphanet Journal of Rare Diseases, 2010
- Clinical and biochemical studies in mucopolysaccharidosis type II carriersJournal of Inherited Metabolic Disease, 2009
- Molecular basis of multiple sulfatase deficiency, mucolipidosis II/III and Niemann–Pick C1 disease — Lysosomal storage disorders caused by defects of non-lysosomal proteinsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Alpha-mannosidosisOrphanet Journal of Rare Diseases, 2008
- Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disordersJournal of Inherited Metabolic Disease, 2006
- Mucopolysaccharidosis type II in females: Case report and review of literaturePediatric Neurology, 2005